The regulation of muscle anabolism and catabolism by IGF1 and myostatin as well as inflammation have proven to be promising targets to protect from sarcopenia in general, and novel drug developments in these areas should be applied to pre-clinical models of CKD. Here, MSTN is linked to sarcopenia.